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ABSTRACT 
Expression of HLA-C varies widely across individuals in an allele-specific 
manner. This variation in expression can influence efficacy of the immune 
response, as shown for infectious and autoimmune diseases. MicroRNA 
binding partially influences differential HLA-C expression, but the additional 
contributing factors have remained undetermined. Here we demonstrate using 
functional and structural analyses that HLA-C expression is modulated not just 
at the RNA level but also at the protein level. Specifically, we show that 
variation in exons 2 and 3, which encode the α1/α2 domains, drives differential 
expression of HLA-C allomorphs at the cell surface by influencing the 
structure of the peptide-binding cleft and the diversity of peptides bound by 
the HLA-C molecules. Together with our phylogenetic analyses, these results 
highlight the diversity and long-term balancing selection of regulatory factors 
that modulate HLA-C expression.  
 
The human leukocyte antigen (HLA) gene locus is one of the most diverse regions of 
the human genome, with extreme polymorphism and associations with a large 
number of human diseases1. HLA molecules have diverse clinical implications in 
infectious and autoimmune diseases, cancer, transplantation, and in pregnancy2,3. 
While antigenic specificity is important in dictating the immune response driven by 
! 3 
the HLA molecule, HLA protein levels at the cell surface also play an important role in 
controlling the strength of the immune response4,5. Indeed, cytokine-driven up-
regulation of cell surface HLA in an acute infection highlights the importance of HLA 
expression levels in mediating host defence against pathogens6.  
 
HLA class I molecules, encoded by HLA-A, HLA-B and HLA-C, are highly 
polymorphic and can bind and present a range of intracellular peptides to cytotoxic 
CD8+ T cells, as well as regulate innate immune responses by interacting with killer 
cell immunoglobulin-like receptors (KIR) expressed on natural killer (NK) cells2,3. 
While much is known regarding the role of HLA-A and HLA-B molecules in protective 
and aberrant immunity, comparatively little is known about HLA-C. Compared to its 
counterparts, HLA-C is expressed at lower cell surface levels, is less polymorphic, 
and has evolved to have more extensive interactions with KIRs, thereby playing a key 
role in regulating NK cell responses7-10.  
 
HLA-C expression varies widely in an allele-specific manner4,11 and this diversity is 
an important determinant in influencing disease outcome, especially as observed in 
the case of HIV-1 infection4,12-14. Thus, high HLA-C protein expression in the host has 
been associated with protection against the HIV-1 virus, increased cytotoxic T 
lymphocyte responses and increased frequency of viral escape mutations, 
suggesting that higher HLA-C expression exerts a selection pressure on the virus4, 
which is in line with the recently discovered virus-mediated down-regulation of HLA-C 
expression15. In contrast, high HLA-C expression levels correlate with increased risk 
of Crohn’s disease4,11, and in cases of unrelated hematopoietic transplantation, with 
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poor outcome and graft-versus-host disease5. The divergent effects of HLA-C 
expression on infectious and autoimmune diseases, combined with evidence for the 
recent origin of mutations that influence expression16, suggest a dynamic 
evolutionary balance between positive and negative gene regulation, which can shift 
with the epidemiological cycling of specific pathogens.  
 
There has been a wide interest in identifying factors that influence differential 
expression of HLA-C molecules. A single nucleotide polymorphism 35 kb upstream of 
HLA-C (-35 C/T) was correlated with HIV-1 viral load and HLA-C expression in 
people of European ancestry12,14,17. However, it was subsequently shown that this 
variant was not causative, and was in linkage disequilibrium with another variant in 
the 3’ untranslated region (UTR) of HLA-C, which is a polymorphic microRNA binding 
site for miR-148a. HLA-C alleles that have an intact miR-148a binding site, such as 
C*07 and C*03 amongst others, have low expression as a result of inhibition by the 
microRNA, whereas other HLA-C alleles (e.g. C*05, C*08) that escape miR-148a 
binding due to a deletion in the miR binding site, are expressed at higher levels. This 
insertion/deletion polymorphism in the 3’UTR of HLA-C is only fractionally 
responsible for the differential surface expression of HLA-C alleles13. Variation in 
miR-148a expression itself has also been shown to further influence HLA-C levels. 
However, this still does not fully account for the variation in expression of HLA-C 
alleles with an intact miR-148a binding site, and has no impact on those alleles that 
escape miR-148a regulation11. Alleles of HLA-C show a continuous rather than a 
bimodal expression pattern, suggesting that additional factors with stronger effects 
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than the miR binding site are primarily responsible for influencing differential HLA-C 
surface expression13.  
 
To further understand the mechanisms responsible for differential HLA-C expression, 
we chose two HLA-C alleles, C*05 and C*07, which are commonly found at allele 
frequencies ranging between 3-14% (C*05) and 18-38% (C*07) in Caucasian 
populations18, have high and low expression, respectively, and differ in the 3’UTR 
miR-148a binding site variant. Using a series of functional and structural analyses, 
we show that variation in exons 2 and 3, which encode the antigen-binding α1 and 
α2 domains of HLA-C molecules, contributes to differential cell surface expression of 
these HLA-C allomorphs. This regulation is found to be post-transcriptional as the 
differential cell surface expression does not correlate with mRNA levels. Furthermore, 
we observe that HLA-C*07 has a deeper and narrower antigen-binding cleft than the 
relatively flat peptide-binding cleft of HLA-C*05. In line with this, HLA-C*05 binds a 
larger range of peptides than HLA-C*07, which can stabilise it on the cell surface, 
hence offering a potential explanation for the differential cell surface expression of 
these HLA-C allomorphs. 
 
RESULTS 
Differential expression of HLA-C alleles 
To investigate the mechanisms responsible for differential expression of HLA-C 
molecules, we selected two common HLA-C alleles, HLA-C*05:01:01:01 (referred to 
as C*05) and HLA-C*07:02:01:03 (referred to as C*07), that differ in expression 
levels, and have either a disrupted (C*05) or intact (C*07) miR-148a binding site, 
! 6 
respectively. To study the involvement of the different parts of the HLA-C gene in 
contributing towards differential surface expression, we generated hybrid C*05 and 
C*07 genomic constructs. One half of these hybrid constructs, consisting of the 
promoter, 5’UTR, exons 1-3 and introns 1, 2 and part of intron 3, was taken from the 
human HLA-C*05 or HLA-C*07 alleles, whilst the second half of the constructs were 
identical, and consisted of part of intron 3, exons and introns 4-8, and the 3’UTR of 
the murine H-2Kb allele (Fig. 1a); this allowed us to exclude the involvement of the 
miR-148a binding in differential HLA-C expression levels. Importantly, similar hybrid 
constructs for other HLA class I genes have been described before, and shown to 
retain the peptide-binding specificity of the HLA allele19. The C*05 and C*07 hybrid 
constructs were transfected into HLA class I-negative 721.221 cells along with a GFP 
plasmid to control for transfection efficiency, and the level of HLA-C surface 
expression on transfected cells was determined by flow cytometry. We observed a 
~2-fold higher expression of HLA-C*05 on the cell surface of transfected cells, in 
comparison to cells that expressed HLA-C*07 (Fig. 1b,c and Supplementary Fig. 1a). 
This relative expression difference between C*05 and C*07 transfected cells was 
physiologically relevant as it was comparable to the relative difference in expression 
between HLA-C*05 and HLA-C*07 on human peripheral blood lymphocytes, which is 
reported to be between 1.5 and 2-fold4. This was of particular interest considering 
that both our hybrid constructs had an identical 3’UTR, as well as a region starting 
from a part of intron 3 until, and including, exon 8. These findings therefore indicated 
that variations either in the promoter, 5’UTR, exons 1-3 (which includes the peptide-
binding cleft) or introns 1-3, of HLA-C*05 and HLA-C*07 were contributing to the 
differential HLA-C expression. 
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Influence of the promoter/5’UTR of HLA-C on gene expression  
To test whether the promoter/5’UTRs of the HLA-C*05 and HLA-C*07 alleles were 
driving the protein-level differences that we observed, we cloned their 
promoter/5’UTR sequences (including a region 776 or 766 bp prior to the start codon 
respectively) upstream of the luciferase gene in a promoter-less vector (Fig. 2a). HEK 
293T cells and 721.221 cells were transfected with these C*05-luciferase and C*07-
luciferase constructs and relative luciferase activity was measured. Surprisingly, the 
promoter/5’UTR of C*07 led to a significantly (~2-fold) higher expression of the 
luciferase reporter gene in comparison to the C*05 promoter (Fig. 2b,c) - an effect 
which was in the opposite direction of what was observed on the cell surface of C*05- 
and C*07-transfected cells. This differential effect of the promoter/5’UTR of C*07 on 
luciferase expression has been evidenced in a previous study, that included the 
region of its core promoter, and reported that the core promoter of C*07 was 
significantly more active than its C*06 counterpart20. To assess how the promoter 
directly influenced expression of the HLA-C molecules, we swapped the 
promoter/5’UTR of C*05 and C*07, and generated new hybrid constructs (Fig. 2d), 
which were transfected into 721.221 cells. Swapping of the promoters did not result 
in a change in cell surface expression of C*05 and C*07: C*05 was consistently 
expressed at higher levels (~2-fold relative to C*07) on the cell surface, irrespective 
of the promoter/5’UTR driving its transcription (Fig. 2e,f and Supplementary Fig. 1b). 
Thus, despite having a seemingly weaker promoter/5’UTR region, the cell surface 
protein levels of HLA-C*05 remained significantly higher as compared to HLA-C*07. 
As the variation in the promoter/5’UTR of these alleles could not explain their 
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differential protein expression, this inferred that the relevant region was between 
exons and introns 1-3.  
 
Variation in exons 2 and 3 affects differential HLA-C expression 
To specifically investigate if the exonic coding region of HLA-C could have a direct 
effect on HLA-C expression levels, we used a lentiviral expression system, where the 
expression of the coding region of C*05 and C*07 was driven by a common lentiviral 
promoter. Although the anti-HLA antibody (W6/32) that we used to stain for HLA-C 
expression has monomorphic specificity and binds fully assembled HLA class I 
molecules with equal affinity21,22, we included an N-terminal hemagglutinin (HA) tag in 
these constructs as an additional control. To establish the validity of the system, HA-
tagged C*05 and C*07 constructs including the sequence of exons 1-8 of these 
alleles were generated (Fig. 3a), and 721.221 cells were transduced with the 
respective C*05 and C*07 lentivirus at equivalent multiplicity of infection (normalised 
using GFP, expressed in tandem from the lentiviral expression vector). The 
differential expression pattern of HLA-C, detected on the cell surface by the anti-HLA 
(Fig. 3b,d), and anti-HA (Fig. 3c,e) antibodies, was preserved in these lentiviral-
transduced cells at levels similar to those observed with the transiently transfected 
cells (Fig. 1c and Fig. 2f). Importantly, the expression difference between C*05 and 
C*07 was seen to be consistent between HA-tagged and non-tagged HLA-C 
constructs, suggesting that the HA tag, itself, does not change the HLA-C expression 
pattern or cellular characteristics, also shown by a previous study comparing HA-
tagged and non-tagged HLA class I molecules23. To then test whether variation in α1 
and α2 domains of the HLA-C molecules was responsible for the differential 
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expression, we generated modified lentiviral expression constructs that contained 
only exons 1-3 of the C*05 and C*07 alleles and exons 4-8 of the murine H-2Kb allele 
(Fig. 4a). Interestingly, cell surface staining revealed a significant and consistently 
high expression (~1.7-fold) of C*05 in comparison to C*07 in 721.221 cells 
transduced with the modified lentivirus, demonstrating that variation in the α1/α2 
domains of HLA-C was controlling the differential HLA-C expression (Fig. 4b-e). 
Furthermore, this appeared to be a post-transcriptional event, as no significant 
changes in HLA-C were observed at the mRNA level, as tested using exon-spanning 
QPCR primers designed for an H-2Kb region common to both HLA-C constructs 
(Supplementary Fig. 2). Additionally, staining for HLA-C after fixation and 
permeabilisation of transduced cells (Supplementary Fig. 3 and Supplementary Fig. 
4), or quantification of HLA-C protein levels by immunoblotting of whole cell lysates 
(Supplementary Fig. 5 and Supplementary Fig. 6), did not reveal a difference in total 
protein-level expression between C*05 and C*07, despite the cell-surface difference 
(Fig. 3 and 4). This may be related to accumulation and retention of HLA-C folding 
intermediates inside the cell, prior to successful peptide loading and export to the cell 
surface, such that total protein expression is unaffected but there is a differential 
expression level at the plasma membrane24,25. Taken together, these data 
demonstrate that variation in the coding region of HLA-C, specifically the α1 and α2 
domains, can drive differential HLA-C expression at the cell surface.  
 
HLA-C*05 and HLA-C*07 possess contrasting antigen-binding clefts 
To elucidate the role of α1/α2 domains and the peptide-binding cleft of HLA-C on 
differential expression, we solved the structure of HLA-C*05 in complex with a HLA-
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C*05 specific peptide, SAEPVPLQL (SAE)26, and HLA-C*07 in complex with a HLA-
C*07 specific peptide, RYRPGTVAL (RYR)27 (Supplementary Table 1).  
Within the HLA-C*05-SAE complex, there are four main anchor residues, P1-Ser, P3-
Glu, P7-Leu and P9-Leu. The P1-Ser is surrounded by seven aromatic residues, 
arising from the floor of the antigen-binding cleft (Tyr7, Tyr67 and Phe33) and from 
the α1 and α2 helices (Tyr59, Tyr171, Tyr159 and Trp167), as well as hydrogen 
bonding to Lys66 (Fig. 5a). The P3-Glu forms a salt bridge with Arg156 and Arg97, 
and has a hydrophobic interaction with Tyr159 (Fig. 5b). In addition, the P7-Leu 
places its hydrophobic side chain underneath Arg156 and binds within a hydrophobic 
pocket lined by Phe116 and Trp147 (Fig. 5c). Finally, the P9-Leu is anchored in the F 
pocket of HLA-C*05 and interacts with the 2 hydrophobic residues, Leu81 and Leu95 
(Fig. 5d).  
The structure of HLA-C*07 in complex with the RYR peptide revealed canonical P2-
Tyr and P9-Leu anchor residues, a large network of interactions at P1-Arg and a 
secondary anchor residue at P3-Arg. The P1-Arg in HLA-C*07 was stabilised by 
aromatic residues, similarly to the P1-Ser of the SAE peptide in HLA-C*05 (not 
shown), with an additional salt bridge formed with the Glu63 (Fig. 5e). The large P2-
Tyr sat into the B pocket, stabilised by hydrogen bond with Asp9 and van der Waals 
interactions with Tyr7 and Tyr67 (Fig. 5e). In contrast to HLA-C*05, the B pocket of 
HLA-C*07 is deeper due to the smaller polymorphic residue at position 9, which is 
Asp in HLA-C*07, as opposed to Tyr in HLA-C*05. The P3-Arg of the RYR peptide, 
which was buried within the antigen-binding cleft, acted as a secondary anchor 
residue when binding to the HLA-C*07 molecule. The absence of the Arg156 in HLA-
C*07 (replaced with a smaller and hydrophobic Leu156) allowed the P3-Arg of the 
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RYR peptide to fit inside the cleft of the HLA-C*07 molecule (Fig. 5f). The buried 
conformation of the P3-Arg is facilitated by the presence of small residues at position 
9 (Asp!Tyr) and 99 (Ser!Tyr) in the cleft of HLA-C*07 that allow enough space for 
the Arg97 to move away from the P3-Arg (Fig. 5f). P3-Arg is stabilised by a hydrogen 
bond with the Gln70 and salt bridge with Asp114. The P9-Leu interacts with the HLA-
C*07 in a similar fashion to the analogous interaction observed for HLA-C*05-SAE 
complex (not shown).  
HLA-C*05 and HLA-C*07 differ by 22 residues, of which 15 are located within the 
α1/α2 domains, with 10 of these being involved in peptide interactions, namely Tyr9, 
Thr73, Asn77, Lys80, Tyr99, Asn114, Phe116, Trp147, Glu152 and Arg156 (Fig. 5g). 
While HLA-C*05 uses a large network of aromatic residues in both the A and B 
pockets, the HLA-C*07 B pocket lacks two of these tyrosines (Tyr9 ! Asp9 and 
Tyr99 ! Ser99) (Fig. 6a). The presence of these smaller residues and Asp9 in HLA-
C*07 is consistent with the preference of P2 Arg/Tyr for HLA-C*07-restricted 
peptides, as previously reported28. Similarly, the F pocket of HLA-C*05 was ‘filled’ by 
large aromatic residues (Phe116 and Trp147), which were absent from HLA-C*07 
(Ser116 and Leu147) (Fig. 6b). In addition to the larger Trp147, the hinge of the α2-
helix of HLA-C*05 differs from HLA-C*07 by two other large residues, namely Glu152 
(Ala152 in HLA-C*07) and Arg156 (Leu156 in HLA-C*07). These large residues 
located on the α2-helix of HLA-C*05 open the antigen-binding cleft by almost 3Å 
(residues 149 to 151) (Fig. 6c), while the rest of the cleft was similar (r.m.s.d. of 0.62 
Å on the Cα of the α1-α2 domains). 
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Overall the B and F pockets, binding the characteristic anchor residues at P2 and the 
C-terminus of HLA class I-restricted epitopes, contain large aromatic residues in 
HLA-C*05 that are absent in HLA-C*07. Consequently, the antigen-binding cleft of 
HLA-C*05 is composed of residues with large side chains, and accordingly offers a 
more shallow cleft (volume 1200 Å3, Fig. 6d) in contrast to the HLA-C*07 cleft that is 
deeper and narrower with a larger volume (1500 Å3, Fig. 6e). Therefore, the 
polymorphic residues are ‘filling’ the cleft of HLA-C*05 that represents a relatively 
shallow groove, providing a ‘peptide-landing platform’ for HLA-C*05, instead of the 
traditional groove generally found in HLA molecules that are more prone to have 
preference for specific anchoring motifs (Fig. 6d,e).  
 
The apparent ‘flat cleft’ of HLA-C*05 might allow binding of a more diverse range of 
peptides, which could impact the stability of the peptide-HLA-C complexes and 
contribute to differential HLA-C expression at the cell surface. To test this, we 
refolded both HLA-C*05 and HLA-C*07 with four different peptides, including two 
HLA-C*05 peptides (a self-peptide, ITASRFKEL (ITA)29, and the viral peptide SAE26 
and two HLA-C*07 peptides (two self peptides, RYRPGTVAL (RYR)27 and 
KYFDEHYEY (KYF)30), and compared the thermal stability of these peptide-HLA-C 
complexes. In line with the structural data, HLA-C*07 showed a preference for P2 
Arg/Tyr, and its stability was 5-10°C higher when refolded with the HLA-C*07 
peptides, RYR and KYF, in comparison to its stability with the HLA-C*05 peptides, 
SAE and ITA. Contrastingly, the HLA-C*05 molecule exhibited the same thermal 
stability with the HLA-C*05 peptides as well as the HLA-C*07 peptides, with an 
average Tm of ~52°C (Supplementary Table 2). In line with the structural analyses, 
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these results indicate that, unlike for HLA-C*07, the stability of HLA-C*05 was less 
reliant on the sequence of the bound peptides, and that HLA-C*05 might be more 
permissive than HLA-C*07 in its peptide-binding motif, which could impact its 
differential expression pattern.  
 
Comparison of the peptides bound by HLA-C*05 and HLA-C*07 
To compare the peptide repertoire of HLA-C*05:01 and HLA-C*07:02, we isolated 
these HLA class I molecules from the cell surface of equal numbers of C*05 and 
C*07 transfected 721.221 cells, and sequenced bound peptides by mass 
spectrometry.  
A total of 1870 specific peptides were identified from HLA-C*05 molecules 
(Supplementary Data File 1). The majority of these peptides (70.6 %) were 8-10 
amino acids in length, with nonamers being the most abundant species (46.7 %) (Fig. 
7a). Analysis of nonameric peptides revealed three positions with conserved residues 
(P2, P3 and P9). The P3 position was by far the most conserved with 80 % of the 
peptides having an Asp at this position, and a further 15 % having Glu. The P2 
position optimally preferred a small uncharged residue such as Ala (40 %), and to a 
smaller extent Ser (13 %) and Val (11 %). At the P9 position, the majority of the 
peptides carried a hydrophobic residue, with 45 % of the peptides carrying a Leu, 
with smaller contributions from Phe (17 %), Met (13 %) and Val (10%) (Fig. 7c).  
A total of 580 specific peptides were identified from HLA-C*07 molecules 
(Supplementary Data File 1). The majority of the peptides observed (54.1 %) were 
also 8-10 amino acids in length, with nonamers being the most abundant species 
(39.8%), however, this was less than that observed for HLA-C*05 (Fig. 7b). Analysis 
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of nonamers revealed only two positions with conserved residues (P2 and P9). The 
P2 position was most conserved with Arg being most dominant (40 %), closely 
followed by Tyr (38 %), and a small contribution from Lys (13 %). The P9 position 
preferred a hydrophobic residue with Leu (31 %) being most conserved, however 
HLA-C*07 also appeared to accept larger hydrophobic residues such as Tyr (30 %), 
Phe (17 %) and Met (13 %) (Fig. 7d). 
In line with the structural analysis, these peptide-repertoire data demonstrate that the 
number of distinct peptides bound by HLA-C*05 were 3-fold higher than those bound 
by HLA-C*07, in agreement with the higher relative expression of HLA-C*05 on the 
cell surface. Collectively, these data provide insight into how the α1/α2 domains and 
the peptide-binding cleft of HLA-C molecules can not only have a direct influence on 
HLA stability and peptide repertoire, but also influence cell surface expression levels.  
 
Phylogenetic analysis of HLA-C sequences 
To assess the evolutionary origin of the variation in exons 2 and 3 of HLA-C alleles, 
which we show influences HLA-C expression levels, we performed sequence 
alignments of the exon 2 and 3 region of HLA-C alleles with the available non-human 
primate MHC-C alleles, and inferred their phylogenetic relationship (Fig. 8). Within 
the exon 2 and 3 sequence, the HLA-C*07 alleles seemed more closely related to a 
set of chimpanzee Patr-C alleles, than to HLA-C*05 alleles. This indicated a 
maintenance of HLA-C*07-like alleles in non-human primates, whereas the HLA-
C*05-like alleles have only been found in humans. As expected, there was also 
evidence for additional diversity, and groups of chimpanzee-specific MHC-C and 
human-specific HLA-C sequences.   
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Our study, combined with previous work13, suggests that there are three regions of 
HLA-C that have the ability to regulate differential HLA-C expression i.e. the 
promoter/5’UTR, exons 2 and 3, and the 3’UTR. To compare the diversity of genetic 
variants in these three regions, we performed phylogenetic analysis for each of these 
regions across a range of HLA-C alleles (Supplementary Fig. 7). These phylogenetic 
trees were then used to calculate phylogenetic distances between HLA-C alleles for 
each of these regions. Using HLA-C*05 and HLA-C*07 as references, the degree of 
similarity between a HLA-C allele and HLA-C*05 or HLA-C*07 was determined for 
each region, and plotted as a grid (Fig. 9). This in silico analysis revealed a wide 
range of variation in the three genetic regions that regulate HLA-C expression, which 
could be related to the observed continuous expression pattern of HLA-C alleles. For 
example, C*04 alleles, which have been shown to be expressed at high levels at the 
cell surface4, appear to be more similar to C*05 than to C*07 in the promoter/5’UTR, 
and exon 2 and 3 sequence. This is particularly interesting for C*04, as, based on 
binding of miR-148a in the 3’UTR of its mRNA13, and its similarity to C*07 in the 
3’UTR, it would have been predicted to be a low-expresser (Fig. 9). These patterns of 
genetic diversity suggest that a combination of variants spread throughout the HLA-C 
gene region, and perhaps additional factors, all contribute towards allele-specific 
differential expression of HLA-C at both the transcript and protein levels. 
 
DISCUSSION 
In this study, we sought to understand the mechanisms that contribute to differential 
expression of HLA-C molecules. By using a comparison between two common HLA-
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C alleles, HLA-C*05 and HLA-C*07, we demonstrate that variation in exons 2 and 3 
of HLA-C, that encode for the peptide-binding α1/α2 domains, contributes to 
differential cell surface HLA-C protein expression. While HLA-C*05 and HLA-C*07 
levels remain unchanged at the transcript and total protein level, we find a significant 
difference in their relative cell surface expression, with HLA-C*05 being expressed at 
high levels on the cell surface. Using structural, thermal stability and peptide-
repertoire comparisons, we demonstrate that the peptide-binding cleft of HLA-C*05 is 
more permissive and is filled with large aromatic residues, which is not the case for 
HLA-C*07. Our data demonstrate that instead of forming a groove as in HLA-C*07, 
the peptide-binding cleft of HLA-C*05 forms a flatter ‘peptide-landing platform’, that 
allows binding of a larger range of peptides, which can stabilise the HLA-C molecule, 
in turn affecting its expression levels on the cell surface.  
 
We found that the promoter/5’UTR of HLA-C, which, in this study, spanned up to 
776/766 bases upstream of the start codon, did not directly impact the differential 
surface expression of HLA-C alleles. This was surprising considering that the same 
promoter/5’UTR region differentially affected the expression of the luciferase reporter 
gene. A previous study suggested that an enhancer κB element in the core HLA-C 
promoter was responsible for its differential effect on the luciferase reporter, however, 
they did not investigate the direct effects of the core promoter on HLA-C expression 
levels20. We do not find any evidence that the region of the promoter/5’UTR of HLA-C 
tested in this study has any significant effect on HLA-C mRNA levels, however, it is 
feasible that elements outside of the tested sequence could impact mRNA 
expression of HLA-C alleles.  
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Studies on HLA molecules have largely focussed on their peptide binding 
specificities, whilst there has been limited emphasis on the regulatory mechanisms 
that control their differential allele expression and the ensuing functional implications. 
Small differences in expression level of MHC/HLA genes can influence response to 
pathogens, tumours, autoimmunity, as well as transplantation, potentially through 
both the acquired and innate immune response pathways4,5,11,31-34. Hence, even a 
two-fold difference that is observed between HLA-C allotypes, such as HLA-C*05 and 
HLA-C*07, is likely to have functional consequences in influencing the efficacy of the 
immune response. HLA-C is expressed at lower levels and is limited in polymorphism 
compared to its counterparts, HLA-A and HLA-B7-10. However, HLA-C is a 
prototypical KIR ligand and is important in the regulation of NK cell activity7. Although 
KIRs are capable of binding multiple HLA-C allotypes, it is plausible that differences 
in expression of HLA-C allotypes have a downstream influence on KIR signalling and 
NK cell function. The broad peptide specificity of KIRs35 raises the question of 
whether alleles such as HLA-C*05, whose stability is less reliant on the sequence of 
the bound peptide, are potentially better KIR ligands. 
 
A previous study that attempted to understand the peptide-binding specificities of 
HLA-C molecules suggested that no conservation at P2 is observed for HLA-C*05-
restricted peptides, hence allowing a greater diversity of amino acids to bind the B 
pocket28. However, the authors described that a HLA-C*05-specific peptide would 
have a preference for an Asp at position 3. Our structure of the HLA-C*05-SAE 
complex showed that P3-Glu forms a salt bridge with the polymorphic residue Arg156 
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(Leu156 in HLA-C*07), and a P3-Asp would be suited to interact in the same fashion. 
Furthermore, results from our thermal stability assay show that smaller residues, 
such as P3-Ala, could also be readily accommodated within HLA-C*05. Our peptide-
elution data demonstrate that HLA-C*05 has a preference for a small residue at P2, 
which fits well with its shallow and flat peptide-binding cleft, and its ability to bind a 
greater number and range of peptides.  
 
Post-transcriptional mechanisms such as inefficient peptide binding or association 
with chaperons such as TAP (transporter associated with peptide-loading) or tapasin 
have been proposed to contribute towards lower surface expression of HLA-C in 
comparison to HLA-A and HLA-B24,25,36, however, this has not yet been reported for 
differential surface expression of HLA-C alleles.  
 
Studies of chicken MHC have reported an inverse correlation between diversity of 
peptide repertoire and cell surface MHC class I expression, with low expression 
correlating with resistance to Marek’s disease37,38. However, structural analyses of 
high- and low-expressing chicken MHC class I molecules importantly reveal that the 
width of the peptide-binding groove is large in low-expressing molecules, and narrow 
in high-expressing MHC class I molecules37-39. Similarly, a difference in thermal 
stability is correlated to surface expression levels40. The presentation of peptides on 
the cell surface of chicken MHC is reliant on the peptide-translocation specificity of 
TAP, which is known to vary between chicken haplotypes and by TAP 
polymorphism39,40; such peptide-translocation specificity of TAP is not found in 
humans41.  
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Our results, combined with previous work, show that HLA-C expression is modulated 
by multiple factors acting at several levels, from transcription to miRNA binding and 
peptide selectivity mediated by the antigen-binding cleft – consequently leading to a 
net effect that determines abundance at the cell surface (Fig. 10). Such diversity 
points to a complex evolutionary history. Here, we show that the antigen-binding 
cleft-encoding sequence of exons 2 and 3 of C*07-like alleles has been maintained in 
primates for millions of years and can be found in modern populations of 
chimpanzees and other species, while no C*05-like alleles were found in the 
chimpanzee sequences available. By contrast, the 3’ miRNA binding site 
polymorphism seems to have arisen since the split of the human and chimpanzee 
ancestors, through a gene conversion event from an HLA-B sequence16. Similarly, 
there seems to be no evidence for shared polymorphism in the promoter region, 
likewise indicating that these variants have also arisen since the species diverged42. 
This complex evolutionary and regulatory landscape is suggestive of an ever-
changing selective regime, perhaps resulting from transient selection for up- or down-
regulation of specific groups of alleles with particular binding specificities, in response 
to particular pathogens and endogenous factors such as autoimmunity and 
pregnancy.   
 
METHODS 
Transient transfection assays and constructs 
The C*05 and C*07 hybrid constructs were made by amplifying ~ 2.04 kb and 2.06 kb 
genomic fragments of HLA-C*05:01:01:01 and HLA-C*07:02:01:03 respectively, 
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which contained 776 bp or 766 bp of the respective HLA 5’UTR and exons 1-3 up to 
a midpoint in intron 3, which was fused to a ~ 3.58 kb fragment of the genomic H-2Kb 
gene, beginning at a midpoint in intron 3 and containing exons 4-8 and the H-2Kb 
3’UTR. For experiments with swapped promoters/5’UTR, additional hybrid constructs 
were made where the 5’ flanking region of the HLA genes was interchanged, such 
that the HLA-C*05:01:01:01 promoter/5’UTR was fused to the exon 1-3 sequence of 
HLA-C*07:02:01:03, and vice versa. The region from the genomic H-2Kb gene was 
the same as described above. These hybrid constructs were transfected into 721.221 
cells using optimised electroporation conditions (260V, 1070μF, ∞ resistance) using a 
Genepulser II (Bio-Rad). A limiting concentration of the pmax-GFP plasmid (Lonza) 
was co-transfected as a transfection control. The cells were harvested 48 hours post-
transfection, and used for flow cytometry or RNA isolation/QPCR experiments. See 
supplementary information for details. 
 
Luciferase assays 
The promoters/5’UTR of HLA-C*05:01:01:01 (776 bp upstream of the start codon) or 
HLA-C*07:02:01:03 (766 bp upstream of the start codon) genes were cloned into a 
luciferase containing pGL4.14 (Promega) basic promoter-less vector. HEK 293T or 
721.221 cells were transfected with the luciferase constructs containing the 
5’UTR/promoter from either C*05, C*07 or no promoter, along with the co-
transfection of the Renilla luciferase vector, pGL4.74 (Promega), using TransIT 2020 
transfection reagent (for HEK 293T cells) or optimised electroporation conditions (for 
721.221 cells). Cells were lysed after 24 hours (HEK 293T) or 5 hours (721.221) 
post-transfection, and firefly and renilla luciferase activities were measured using 
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dual luciferase reporter assay system (Promega) and the Glomax multi detection 
system (Promega). The firefly luciferase activity was normalised relative to Renilla 
luciferase for each transfection, and the luciferase activity of each reporter construct 
was calculated as a fold change relative to the activity of pGL4.14-basic vector 
lacking a promoter.  
 
Lentiviral expression assays 
The C*05 and C*07 lentiviral expression constructs were made by amplifying the 
cDNA of HLA-C*05:01:01:01 and HLA-C*07:02:01:03 genes from exons 1-8, and 
cloning it into the pHRsinUbEm expression plasmid (a gift from J.M. Boname/ P.J. 
Lehner, University of Cambridge), with the inclusion of the HA tag at the N-terminus 
of C*05 and C*07, just after the signal peptide sequence. For the modified C*05 and 
C*07 lentiviral expression constructs, the cDNA of exons 1-3 from the respective HLA 
genes was fused to the cDNA of exons 4-8 of the murine H-2Kb gene, and cloned 
into the pHRsinUbEm expression plasmid, with inclusion of the N-terminal HA tag. 
See supplementary information for details of viral packaging and transduction. Cells 
were harvested 72 hours post transduction and flow cytometry, RNA isolation/QPCR 
or immunoblotting experiments were performed. 
 
Statistical analysis  
Statistical tests were performed using GraphPad Prism and non-parametric Mann-
Whitney U-tests were used for comparing two experimental groups, with a 5% 
significance level. For swapped promoter analyses, a Bonferroni correction for 
multiple testing was used; considering P=0.05 for four independent hypotheses, the 
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significance threshold used for this analyses was P=0.0125.  
 
Protein expression, purification and crystallisation 
Soluble class I heterodimers of HLA-C*05 and HLA-C*07 heavy chain and full-length 
β2-microglobulin (β2m) were expressed in Escherichia coli as inclusion bodies as 
previously described43. Both HLA molecules were refolded with 4 peptides 
ITASRFKEL, SAEPVPLQL, RYRPGTVAL and KYFDEHYEY and thermal stability 
assay was performed as described in the supplementary information.  
 
Crystallisation, data collection and structure determination 
Crystals of the HLA-C*05-SAE were grown by the hanging-drop, vapour-diffusion 
method at 20°C with a protein/reservoir drop ratio of 1:1, at a concentration of 3 
mg/mL in 10 mM Tris-HCl pH 8, 150 mM NaCl using 1.8 M Na malonate pH 7. The 
HLA-C*05:01-SAE crystals were flash frozen in liquid nitrogen. Crystals of HLA-
C*0702-RYR were grown in 0.1 M HEPES pH 8.5, 2 mM ZnSO4 and 28 % jeffamine 
ED-2001 (Hampton), using the same technique as for the HLA-C*05-SAE crystals. 
The HLA-C*07-RYR crystals were soaked in a mother liquid solution with the addition 
of 25 % ethylene glycol prior to be flash frozen in liquid nitrogen. The data were 
collected on the MX1 beamline at the Australian Synchrotron44, using the ADSC-
Quantum 210 CCD detector (at 100K). Data were processed using the XDS45 and 
scaled using SCALA software46 from the CCP4 suite47. Details of structures 
determination and refinement statistics are provided in the supplementary 
information.  
 
! 23 
Peptide elution  
The HLA class-I negative 721.221 cells stably transfected with HLA-C*05:01 or HLA-
C*07:02 were utilised to obtain the peptide repertoires in a previously described 
manner48,49. In short, HLA class I were purified from a total 4 x 109 721.221 cells for 
each HLA-C using the pan class I antibody W6/32 immobilised and cross-linked to 
protein A resin. Captured HLA-peptide complexes were eluted with 10 % acetic acid. 
The dissociated complexes were further separated by Reversed-phase HPLC to 
isolate and fractionate the bound peptides before analysis with a Q Exactive Hybrid 
Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific)49. Peptides were 
identified by database search using the human UniProtKB/SwissProt database (Feb 
2016) with ProteinPilot V5.0 (SCIEX). A false discovery rate of 5% was applied and 
known contaminant peptides removed from the final list of peptide ligands. Peptides 
of 8 – 14 amino acids in length were then used for analysis. 
 
Phylogenetic analysis of human and chimpanzee HLA-C alleles 
Nucleotide sequences for human and chimpanzee HLA-C alleles were obtained from 
the IMGT database50. All chimpanzee sequences in the database were considered 
and a subset of human sequences was selected in each allele subclass. The region 
of the sequences aligned included exon 2 and 3 region (without the intron) and 
spanned 546 bp for the C*05 and C*07 sequences. Sequences were aligned with 
MUSCLE (v3.8.31)51 and the exon 2 and 3 sequences were extracted from the 
alignment. MrBayes (v3.2.5)52 was used to infer the phylogenetic relationship 
between sequences using the GTR model of nucleotide evolution with rate gamma 
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distributed, running parameters used were nruns=3, nchains=4, ngen=2000000 and 
samplefreq=1000. 
 
Generation of heat-map for comparison of regulatory elements in human HLA-
C alleles 
For extended description see supplementary information. In brief, sequences 
homologous to HLA-C*05:01:01:01 and HLA-C*07:02:01:03 were identified in the 
NCBI nucleotide database using BLAST+ (v. 2.3.0)53. Sequences containing the 
promoter and 5’UTR, exons 2 to 3, and 3’UTR regions were considered for the 
analysis (details in supplementary information). For display on the heat map, one 
representative sequence of each allele type was chosen. To quantify the relative 
similarity between a HLA-C allele and HLA-C*05 and HLA-C*07 in a phylogenetic 
tree, we calculated a metric quantifying the phylogenetic distance between the query 
HLA allele and its relative distance to HLA-C*05 and HLA-C*07 in the specific tree. 
Further details of alignments and generation of phylogenetic trees can be found in 
the supplementary information.  
 
REFERENCES 
1 Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic Acids Res 42, D1001-1006, doi:10.1093/nar/gkt1229 
(2014). 
2 Parham, P. MHC class I molecules and KIRs in human history, health and 
survival. Nat Rev Immunol 5, 201-214, doi:10.1038/nri1570 (2005). 
! 25 
3 Shiina, T., Hosomichi, K., Inoko, H. & Kulski, J. K. The HLA genomic loci map: 
expression, interaction, diversity and disease. J Hum Genet 54, 15-39, 
doi:10.1038/jhg.2008.5 (2009). 
4 Apps, R. et al. Influence of HLA-C expression level on HIV control. Science 
340, 87-91, doi:10.1126/science.1232685 (2013). 
5 Petersdorf, E. W. et al. HLA-C expression levels define permissible 
mismatches in hematopoietic cell transplantation. Blood 124, 3996-4003, 
doi:10.1182/blood-2014-09-599969 (2014). 
6 Koeffler, H. P., Ranyard, J., Yelton, L., Billing, R. & Bohman, R. Gamma-
interferon induces expression of the HLA-D antigens on normal and leukemic 
human myeloid cells. Proc Natl Acad Sci U S A 81, 4080-4084 (1984). 
7 Bashirova, A. A., Martin, M. P., McVicar, D. W. & Carrington, M. The killer 
immunoglobulin-like receptor gene cluster: tuning the genome for defense. 
Annu Rev Genomics Hum Genet 7, 277-300, 
doi:10.1146/annurev.genom.7.080505.115726 (2006). 
8 Snary, D., Barnstable, C. J., Bodmer, W. F. & Crumpton, M. J. Molecular 
structure of human histocompatibility antigens: the HLA-C series. Eur J 
Immunol 7, 580-585, doi:10.1002/eji.1830070816 (1977). 
9 Zemmour, J. & Parham, P. Distinctive polymorphism at the HLA-C locus: 
implications for the expression of HLA-C. J Exp Med 176, 937-950 (1992). 
10 Apps, R. et al. Relative expression levels of the HLA class-I proteins in normal 
and HIV-infected cells. J Immunol 194, 3594-3600, 
doi:10.4049/jimmunol.1403234 (2015). 
! 26 
11 Kulkarni, S. et al. Genetic interplay between HLA-C and MIR148A in HIV 
control and Crohn disease. Proc Natl Acad Sci U S A 110, 20705-20710, 
doi:10.1073/pnas.1312237110 (2013). 
12 Fellay, J. et al. A whole-genome association study of major determinants for 
host control of HIV-1. Science 317, 944-947, doi:10.1126/science.1143767 
(2007). 
13 Kulkarni, S. et al. Differential microRNA regulation of HLA-C expression and 
its association with HIV control. Nature 472, 495-498, 
doi:10.1038/nature09914 (2011). 
14 Thomas, R. et al. HLA-C cell surface expression and control of HIV/AIDS 
correlate with a variant upstream of HLA-C. Nat Genet 41, 1290-1294, 
doi:10.1038/ng.486 (2009). 
15 Apps, R. et al. HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host Microbe 
19, 686-695, doi:10.1016/j.chom.2016.04.005 (2016). 
16 O'Huigin, C. et al. The molecular origin and consequences of escape from 
miRNA regulation by HLA-C alleles. Am J Hum Genet 89, 424-431, 
doi:10.1016/j.ajhg.2011.07.024 (2011). 
17 Pereyra, F. et al. The major genetic determinants of HIV-1 control affect HLA 
class I peptide presentation. Science 330, 1551-1557, 
doi:10.1126/science.1195271 (2010). 
18 Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features 
for HLA epitopes, KIR and disease and HLA adverse drug reaction 
associations. Nucleic Acids Res 43, D784-788, doi:10.1093/nar/gku1166 
(2015). 
! 27 
19 Borenstein, S. H., Graham, J., Zhang, X. L. & Chamberlain, J. W. CD8+ T cells 
are necessary for recognition of allelic, but not locus-mismatched or xeno-, 
HLA class I transplantation antigens. J Immunol 165, 2341-2353 (2000). 
20 Hundhausen, C. et al. Allele-specific cytokine responses at the HLA-C locus: 
implications for psoriasis. J Invest Dermatol 132, 635-641, 
doi:10.1038/jid.2011.378 (2012). 
21 Apps, R. et al. Human leucocyte antigen (HLA) expression of primary 
trophoblast cells and placental cell lines, determined using single antigen 
beads to characterize allotype specificities of anti-HLA antibodies. 
Immunology 127, 26-39, doi:10.1111/j.1365-2567.2008.03019.x (2009). 
22 Hilton, H. G. & Parham, P. Direct binding to antigen-coated beads refines the 
specificity and cross-reactivity of four monoclonal antibodies that recognize 
polymorphic epitopes of HLA class I molecules. Tissue Antigens 81, 212-220, 
doi:10.1111/tan.12095 (2013). 
23 Kim, E., Kwak, H. & Ahn, K. Cytosolic aminopeptidases influence MHC class I-
mediated antigen presentation in an allele-dependent manner. J Immunol 183, 
7379-7387, doi:10.4049/jimmunol.0901489 (2009). 
24 Neisig, A., Melief, C. J. & Neefjes, J. Reduced cell surface expression of HLA-
C molecules correlates with restricted peptide binding and stable TAP 
interaction. J Immunol 160, 171-179 (1998). 
25 Sibilio, L. et al. A single bottleneck in HLA-C assembly. J Biol Chem 283, 
1267-1274, doi:10.1074/jbc.M708068200 (2008). 
! 28 
26 Addo, M. M. et al. The HIV-1 regulatory proteins Tat and Rev are frequently 
targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. 
Proc Natl Acad Sci U S A 98, 1781-1786, doi:10.1073/pnas.98.4.1781 (2001). 
27 Vales-Gomez, M., Reyburn, H. T., Mandelboim, M. & Strominger, J. L. Kinetics 
of interaction of HLA-C ligands with natural killer cell inhibitory receptors. 
Immunity 9, 337-344 (1998). 
28 Rasmussen, M. et al. Uncovering the peptide-binding specificities of HLA-C: a 
general strategy to determine the specificity of any MHC class I molecule. J 
Immunol 193, 4790-4802, doi:10.4049/jimmunol.1401689 (2014). 
29 Hofmann, S. et al. Rapid and sensitive identification of major histocompatibility 
complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol 
Cell Proteomics 4, 1888-1897, doi:10.1074/mcp.M500076-MCP200 (2005). 
30 Falk, K. et al. Allele-specific peptide ligand motifs of HLA-C molecules. Proc 
Natl Acad Sci U S A 90, 12005-12009 (1993). 
31 Miyadera, H., Ohashi, J., Lernmark, A., Kitamura, T. & Tokunaga, K. Cell-
surface MHC density profiling reveals instability of autoimmunity-associated 
HLA. J Clin Invest 125, 275-291, doi:10.1172/JCI74961 (2015). 
32 Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC 
class I expression, and induces successful antitumor immunotherapy. J Exp 
Med 203, 1259-1271, doi:10.1084/jem.20052494 (2006). 
33 Faroudi, M. et al. Lytic versus stimulatory synapse in cytotoxic T 
lymphocyte/target cell interaction: manifestation of a dual activation threshold. 
Proc Natl Acad Sci U S A 100, 14145-14150, doi:10.1073/pnas.2334336100 
(2003). 
! 29 
34 Thomas, R. et al. A novel variant marking HLA-DP expression levels predicts 
recovery from hepatitis B virus infection. J Virol 86, 6979-6985, 
doi:10.1128/JVI.00406-12 (2012). 
35 Cassidy, S. A., Cheent, K. S. & Khakoo, S. I. Effects of Peptide on NK cell-
mediated MHC I recognition. Front Immunol 5, 133, 
doi:10.3389/fimmu.2014.00133 (2014). 
36 Blais, M. E., Dong, T. & Rowland-Jones, S. HLA-C as a mediator of natural 
killer and T-cell activation: spectator or key player? Immunology 133, 1-7, 
doi:10.1111/j.1365-2567.2011.03422.x (2011). 
37 Chappell, P. et al. Expression levels of MHC class I molecules are inversely 
correlated with promiscuity of peptide binding. Elife 4, e05345, 
doi:10.7554/eLife.05345 (2015). 
38 Koch, M. et al. Structures of an MHC class I molecule from B21 chickens 
illustrate promiscuous peptide binding. Immunity 27, 885-899, 
doi:10.1016/j.immuni.2007.11.007 (2007). 
39 Zhang, J. et al. Narrow groove and restricted anchors of MHC class I molecule 
BF2*0401 plus peptide transporter restriction can explain disease 
susceptibility of B4 chickens. J Immunol 189, 4478-4487, 
doi:10.4049/jimmunol.1200885 (2012). 
40 Tregaskes, C. A. et al. Surface expression, peptide repertoire, and 
thermostability of chicken class I molecules correlate with peptide transporter 
specificity. Proc Natl Acad Sci U S A 113, 692-697, 
doi:10.1073/pnas.1511859113 (2016). 
! 30 
41 Obst, R., Armandola, E. A., Nijenhuis, M., Momburg, F. & Hammerling, G. J. 
TAP polymorphism does not influence transport of peptide variants in mice 
and humans. Eur J Immunol 25, 2170-2176, doi:10.1002/eji.1830250808 
(1995). 
42 Auton, A. et al. A fine-scale chimpanzee genetic map from population 
sequencing. Science 336, 193-198, doi:10.1126/science.1216872 (2012). 
43 Gras, S. et al. The shaping of T cell receptor recognition by self-tolerance. 
Immunity 30, 193-203, doi:10.1016/j.immuni.2008.11.011 (2009). 
44 Cowieson, N. P. et al. MX1: a bending-magnet crystallography beamline 
serving both chemical and macromolecular crystallography communities at the 
Australian Synchrotron. J Synchrotron Radiat 22, 187-190, 
doi:10.1107/S1600577514021717 (2015). 
45 Kabsch, W. Xds. Acta Crystallogr D Biol Crystallogr 66, 125-132, 
doi:10.1107/S0907444909047337 (2010). 
46 Evans, P. Scaling and assessment of data quality. Acta Crystallogr D Biol 
Crystallogr 62, 72-82, doi:10.1107/S0907444905036693 (2006). 
47 Collaborative Computational Project, N. The CCP4 suite: programs for protein 
crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763, 
doi:10.1107/S0907444994003112 (1994). 
48 Schittenhelm, R. B., Dudek, N. L., Croft, N. P., Ramarathinam, S. H. & Purcell, 
A. W. A comprehensive analysis of constitutive naturally processed and 
presented HLA-C*04:01 (Cw4)-specific peptides. Tissue Antigens 83, 174-
179, doi:10.1111/tan.12282 (2014). 
! 31 
49 Dudek, N. L., Croft, N. P., Schittenhelm, R. B., Ramarathinam, S. H. & Purcell, 
A. W. A Systems Approach to Understand Antigen Presentation and the 
Immune Response. Methods Mol Biol 1394, 189-209, doi:10.1007/978-1-
4939-3341-9_14 (2016). 
50 Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. 
Nucleic Acids Res 43, D423-431, doi:10.1093/nar/gku1161 (2015). 
51 Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and 
high throughput. Nucleic Acids Res 32, 1792-1797, doi:10.1093/nar/gkh340 
(2004). 
52 Ronquist, F. et al. MrBayes 3.2: efficient Bayesian phylogenetic inference and 
model choice across a large model space. Syst Biol 61, 539-542, 
doi:10.1093/sysbio/sys029 (2012). 
53 Camacho, C. et al. BLAST+: architecture and applications. BMC 
Bioinformatics 10, 421, doi:10.1186/1471-2105-10-421 (2009). 
54 Dundas, J. et al. CASTp: computed atlas of surface topography of proteins 
with structural and topographical mapping of functionally annotated residues. 
Nucleic Acids Res 34, W116-118, doi:10.1093/nar/gkl282 (2006). 
 
ACKNOWLEDGEMENTS  
We would like to acknowledge the flow cytometry facility at the WIMM, which is 
supported by the MRC HIU; MRC MHU (MC_UU_12009); NIHR Oxford BRC and 
John Fell Fund (131/030 and 101/517), the EPA fund (CF182 and CF170) and by the 
WIMM Strategic Alliance awards G0902418 and MC_UU_12025. We would also like 
to acknowledge use of the facilities and the assistance of Dr. Ralf Schittenhelm at the 
! 32 
Monash Biomedical Proteomics Facility. Work in the authors’ laboratories is 
supported by the UK and Danish Medical Research Councils, The Lundbeck 
Foundation, The Alan and Babette Sainsbury Charitable Fund, the Naomi Bramson 
Trust, the Clinical Neuroimmunology Fund, the Oxford Biomedical Research Centre, 
the Oak Foundation (L.F.), Wellcome Trust (100308/Z/12/Z and 106130/Z/14/Z, L.F.; 
100956/Z/13/Z, G.M.), Australian National Health and Medical Research Council 
(NHMRC), Australian Research Council (ARC) (J.R., A.W.P.), ARC Laureate 
fellowship (J.R.), NHMRC Senior Research Fellowship (1044215, A.W.P.), ARC 
Future Fellowship (FT120100416, S.G.). This project has been funded in part with 
federal funds from the Frederick National Laboratory for Cancer Research, under 
Contract No. HHSN261200800001E.  This Research was supported in part by the 
Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer 
Research.  
 
AUTHOR CONTRIBUTIONS 
G.K. contributed to conception, coordination and design of the study, all experiments 
apart from the protein crystallisation and structural work, and to data analyses, 
drafting and writing of the manuscript. S.G. contributed to all structural experiments 
including protein purifications, stability assays, crystallisations and structure 
determination, and to writing of the manuscript. J.I.M. contributed to structural 
experiments including protein purifications, crystallisations, structure determination, 
and peptide repertoire analysis, and to writing of the manuscript. J.P.V contributed to 
structural experiments including protein purifications, crystallisations, structure 
determination, and peptide repertoire analysis. A.C. performed all phylogenetic 
! 33 
analyses of human and chimpanzee sequences, and contributed to writing of the 
manuscript. T.B. contributed to cloning of HLA-C constructs, cellular transfection 
experiments, flow cytometry, QPCR, and data analyses. S.B.K. contributed to 
optimisation of QPCR experiments. L.T.J. contributed to cloning of HLA-C genomic 
constructs. K.E.A. contributed to experimental design and manuscript editing. C.D. 
contributed to experimental design, data and analyses discussions, and to 
manuscript editing. M.C. provided intellectual input and contributed to manuscript 
editing. G.M. contributed to the conception and design of phylogenetic analyses and 
to writing of the manuscript. A.W.P. contributed to conception and design of the 
peptide repertoire analyses. J.R. contributed to the conception and design of the 
structural work and to writing of the manuscript. L.F. contributed to conception, 
coordination and design of the study, and drafting and writing of the manuscript.  
 
COMPETING FINANCIAL INTEREST: The authors declare no competing financial 
interests 
 
DISCLAIMER: The content of this publication does not necessarily reflect the views 
or policies of the Department of Health and Human Services, nor does mention of 
trade names, commercial products, or organizations imply endorsement by the U.S. 
Government.  
 
FIGURE LEGENDS 
Fig. 1 - Differential expression of HLA-C*05 and HLA-C*07 
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(a) Schematic representation of C*05 (red) and C*07 (blue) genomic constructs; 
construct design is detailed in the methods, murine H-2Kb gene is shown in grey. (b) 
Representative cell surface expression of HLA-C on 721.221 cells transfected with 
the C*05 and C*07 genomic constructs. HLA-C (W6/32) staining is shown on GFP+ 
cells. C*05 (red), C*07 (blue) and vector transfected cells (black) are shown. 
Numbers denote mean fluorescence intensity (MFI) of HLA-C+GFP+ cells. (c) 
Normalised HLA-C (W6/32) expression on GFP+ C*05 and C*07 transfected 721.221 
cells. MFI of W6/32 on the gated HLA-C+GFP+ population/MFI of GFP on GFP+ cells 
is plotted, and shown relative to C*07 transfected cells. Mean ± S.E.M is depicted, 
n=9.  
 
Fig. 2 – The promoter/5’UTR of HLA-C*05 and HLA-C*07 differentially affects 
expression of the luciferase reporter gene, but does not directly impact 
differential cell surface expression of HLA-C 
(a) Schematic representation of the luciferase reporter constructs; construct design is 
detailed in the methods. Luciferase reporter constructs were transfected into (b) HEK 
293T cells, and (c) 721.221 cells, and dual luciferase reporter assays performed on 
cell lysates. Relative light units (RLU) plotted as fold change in luciferase activity of 
the promoter/5’UTR of the HLA-C alleles compared to empty-vector is shown. (d) 
Schematic representation of the C*05 and C*07 genomic constructs with or without 
the swapped promoter/5’UTR. (e) Representative cell surface expression of HLA-C 
on 721.221 cells transfected with the C*05 and C*07 genomic constructs. HLA-C 
(W6/32) staining is shown on GFP+ cells. Histogram colour coding is indicated in the 
panel d, black line represents vector-transfected cells, numbers denote MFI. (f) 
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Normalised HLA-C (W6/32) expression on GFP+ C*05 and C*07 transfected 721.221 
cells. MFI of W6/32 on the gated HLA-C+ GFP+ population/MFI of GFP on GFP+ 
cells is plotted, and shown relative to C*07 transfected cells. Mean ± S.E.M is 
depicted, (b) n=12, (c) n=9, (e, f) n=6-9.  
 
Fig. 3 – Lentiviral expression of HLA-C*05 and HLA-C*07 using exonic 
constructs preserves the expression pattern of HLA-C molecules 
(a) Schematic representation of the HA-tagged C*05 and C*07 lentiviral constructs 
which include the sequence of exon 1-8 from the respective HLA-C alleles; HLA-C 
expression is driven by a common SFFV lentiviral promoter. Representative cell 
surface expression of HLA-C on 721.221 cells transduced with the lentiviral C*05 and 
C*07 constructs. (b) HLA-C (W6/32) staining and (c) HLA-C (HA) staining is shown 
on GFP+ cells. C*05 (red), C*07 (blue) and vector transduced cells (black) are 
shown, numbers denote MFI (d) Normalised HLA-C (W6/32) expression and (e) 
HLA-C (HA) expression on GFP+ C*05 and C*07 transduced 721.221 cells. MFI of 
W6/32 or HA/MFI of GFP, on the GFP+ population is plotted, and shown relative to 
C*07 transduced cells. Mean ± S.E.M is depicted, n=6.  
 
Fig. 4 – Variation in exons 2-3 (α1/α2 domains) of HLA-C is responsible for 
differential expression of C*05 and C*07  
(a) Schematic representation of the modified HA-tagged C*05 and C*07 lentiviral 
constructs which include the sequence of exons 1-3 from the respective HLA-C 
alleles, and sequence of exon 4 – exon 8 of the murine H-2Kb gene; HLA-C 
expression is driven by a common SFFV lentiviral promoter. Representative cell 
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surface expression of HLA-C on 721.221 cells transduced with the modified lentiviral 
C*05 and C*07 constructs. (b) HLA-C (W6/32) staining and (c) HLA-C (HA) staining 
is shown on GFP+ cells. C*05 (red), C*07 (blue) and vector transduced cells (black) 
are shown, numbers denote MFI. (d) Normalised HLA-C (W6/32) expression and (e) 
HLA-C (HA) expression on GFP+ C*05 and C*07 transduced 721.221 cells. MFI of 
W6/32 or HA/MFI of GFP, on the GFP+ population is plotted, and shown relative to 
C*07 transduced cells. Mean ± S.E.M is depicted, n=9-11.  
 
Fig. 5 – Peptide-HLA-C interactions 
The panels (a-d) represent the interaction of the HLA-C*05 molecule (red) with the 
SAE peptide (gray sticks), with the residues involved in the interaction represented as 
stick. The panels (e, f) represent the interaction of the HLA-C*07 molecule (blue) with 
the RYR peptide (orange). The black dashed lines represent the interaction between 
the peptide and HLA molecule. (g) HLA-C*05 α1/α2 domains structure represented in 
cartoon (red) with the polymorphic residues that differ with HLA-C*07 coloured in 
green.  
 
Fig. 6 – Structural comparison of HLA-C*05 and HLA-C*07 
Panels (a, b) represent the HLA-C*05 structure (red) or the HLA-C*07 (blue) based 
on the HLA-C*05 structure in the same orientation. Panel (c) shows the superposition 
of the HLA-C*05 and HLA-C*07 structures, coloured as red and blue, respectively. 
(d, e) Panels show a surface representation of the antigen-binding cleft of HLA-C*05 
(red) and of the HLA-C*07 (blue), calculated using CASTp web server54. 
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Fig. 7 – Comparison of peptide repertoire of HLA-C*05 and HLA-C*07 
Peptide length analysis of (a) HLA-C*05:01 and (b) HLA-C*07:02 transfected 721.221 
cells. Peptide motifs identified for nonamers for (c) HLA-C*05:01 and (d) HLA-
C*07:02 are shown. Residues identified as dominant occur at a frequency of > 30 %, 
strong > 20% and preferred > 10 %. 
 
Fig. 8 - Phylogenetic analysis of human HLA-C and chimpanzee MHC-C 
sequences in the exons 2 and 3 region 
HLA-C exon 2 and exon 3 sequences were aligned and used to infer phylogenetic 
relationship. Nodes are labelled with the estimated posterior for each split in the tree. 
The scale represents expected substitutions per site. HLA-C*05:01:01:01 (red), HLA-
C*07:02:01:03 (blue), other HLA-C alleles (black) and chimpanzee Patr-C alleles 
(black bold) are shown.  
 
Fig. 9 - Patterns of genetic diversity in human HLA-C alleles at three regulatory 
sites 
Each grid represents the similarity between a HLA-C allele and the HLA-
C*05:01:01:01 and HLA-C*07:02:01:03 alleles, and it is coloured based on its 
similarity to C*05. Similarity is determined through phylogenetic analysis at the 
promoter/5’UTR, exon 2-3, and 3’UTR regions. The display of HLA-C subgroup 
alleles is based on their similarity ranking in the exon 2-3 region. Inferred trees 
utilised to extract these similarities are presented in Supplementary Fig. 6.  
 
Fig. 10 - The regulatory landscape of HLA-C expression 
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A combination of variants in the 5’UTR, the antigen-binding cleft, and the 3’UTR, and 
potentially other yet unidentified factors, drive differential HLA-C expression at the 
cell-surface. 
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Fig. 1 - Differential expression of HLA-C*05 and HLA-C*07
(a) Schematic representation of C*05 (red) and C*07 (blue) genomic constructs; construct design is detailed in the methods, murine H-2Kb gene is shown in 
grey. (b) Representative cell surface expression of HLA-C on 721.221 cells transfected with the C*05 and C*07 genomic constructs. HLA-C (W6/32) 
staining is shown on GFP+ cells. C*05 (red), C*07 (blue) and vector transfected cells (black) are shown. Numbers denote mean ﬂuorescence intensity (MFI) 
of HLA-C+GFP+ cells. (c) Normalised HLA-C (W6/32) expression on GFP+ C*05 and C*07 transfected 721.221 cells. MFI of W6/32 on the gated HLA-C
+GFP+ population/MFI of GFP on GFP+ cells is plotted, and shown relative to C*07 transfected cells. Mean ± S.E.M is depicted, n=9. 
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Fig. 2 – The promoter/5’UTR of HLA-C*05 and HLA-C*07 differentially affects expression of the luciferase reporter gene, but does not directly 
impact differential cell surface expression of HLA-C
(a) Schematic representation of the luciferase reporter constructs; construct design is detailed in the methods. Luciferase reporter constructs were transfected 
into (b) HEK 293T cells, and (c) 721.221 cells, and dual luciferase reporter assays performed on cell lysates. Relative light units (RLU) plotted as fold change 
in luciferase activity of the promoter/5’UTR of the HLA-C alleles compared to empty-vector is shown. (d) Schematic representation of the C*05 and C*07 
genomic constructs with or without the swapped promoter/5’UTR. (e) Representative cell surface expression of HLA-C on 721.221 cells transfected with the 
C*05 and C*07 genomic constructs. HLA-C (W6/32) staining is shown on GFP+ cells. Histogram colour coding is indicated in the panel d, black line 
represents vector-transfected cells, numbers denote MFI. (f) Normalised HLA-C (W6/32) expression on GFP+ C*05 and C*07 transfected 721.221 cells. MFI 
of W6/32 on the gated HLA-C+ GFP+ population/MFI of GFP on GFP+ cells is plotted, and shown relative to C*07 transfected cells. Mean ± S.E.M is depicted, 
(b) n=12, (c) n=9, (e, f) n=6-9. 
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Fig. 3 – Lentiviral expression of HLA-C*05 and HLA-C*07 using exonic constructs preserves the expression pattern of HLA-C molecules
(a) Schematic representation of the HA-tagged C*05 and C*07 lentiviral constructs which include the sequence of exon 1-8 from the respective HLA-C alleles; 
HLA-C expression is driven by a common SFFV lentiviral promoter. Representative cell surface expression of HLA-C on 721.221 cells transduced with the 
lentiviral C*05 and C*07 constructs. (b) HLA-C (W6/32) staining and (c) HLA-C (HA) staining is shown on GFP+ cells. C*05 (red), C*07 (blue) and vector 
transduced cells (black) are shown, numbers denote MFI (d) Normalised HLA-C (W6/32) expression and (e) HLA-C (HA) expression on GFP+ C*05 and C*07 
transduced 721.221 cells. MFI of W6/32 or HA/MFI of GFP, on the GFP+ population is plotted, and shown relative to C*07 transduced cells. Mean ± S.E.M is 
depicted, n=6. 
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Fig. 4 – Variation in exons 2-3 (α1/α2 domains) of HLA-C is responsible for differential expression of C*05 and C*07 
(a) Schematic representation of the modiﬁed HA-tagged C*05 and C*07 lentiviral constructs which include the sequence of exons 1-3 from the respective 
HLA-C alleles, and sequence of exon 4 – exon 8 of the murine H-2Kb gene; HLA-C expression is driven by a common SFFV lentiviral promoter. 
Representative cell surface expression of HLA-C on 721.221 cells transduced with the modiﬁed lentiviral C*05 and C*07 constructs. (b) HLA-C (W6/32) 
staining and (c) HLA-C (HA) staining is shown on GFP+ cells. C*05 (red), C*07 (blue) and vector transduced cells (black) are shown, numbers denote MFI. 
(d) Normalised HLA-C (W6/32) expression and (e) HLA-C (HA) expression on GFP+ C*05 and C*07 transduced 721.221 cells. MFI of W6/32 or HA/MFI of 
GFP, on the GFP+ population is plotted, and shown relative to C*07 transduced cells. Mean ± S.E.M is depicted, n=9-11. 
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Fig. 5 – Peptide-HLA-C interactions
The panels (a-d) represent the interaction of the HLA-C*05 molecule (red) with the SAE peptide (gray sticks), with the residues involved in the interaction 
represented as stick. The panels (e, f) represent the interaction of the HLA-C*07 molecule (blue) with the RYR peptide (orange). The black dashed lines 
represent the interaction between the peptide and HLA molecule. (g) HLA-C*05 α1/α2 domains structure represented in cartoon (red) with the polymorphic 
residues that differ with HLA-C*07 coloured in green. 
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Fig. 6 – Structural comparison of HLA-C*05 and HLA-C*07
Panels (a, b) represent the HLA-C*05 structure (red) or the HLA-C*07 (blue) based on the HLA-C*05 structure in the same orientation. Panel (c) shows the 
superposition of the HLA-C*05 and HLA-C*07 structures, colour as red and blue, respectively. (d, e) Panels show a surface representation of the antigen-
binding cleft of HLA-C*05 (red) and of the HLA-C*07 (blue) respectively, calculated using CASTp web server50.
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Fig. 7 – Comparison of peptide repertoire of HLA-C*05 and HLA-C*07
Peptide length analysis of (a) HLA-C*05:01 and (b) HLA-C*07:02 transfected 721.221 cells. Peptide motifs identiﬁed for nonamers for (c) HLA-C*05:01 and (d) 
HLA-C*07:02 are shown. Residues identiﬁed as dominant occur at a frequency of > 30 %, strong > 20% and preferred > 10 %.
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Fig. 8 - Phylogenetic analysis of human HLA-C and chimpanzee MHC-C sequences in the exons 2 and 3 region
HLA-C exon 2 and exon 3 sequences were aligned and used to infer phylogenetic relationship. Nodes are labelled with the estimated posterior for each split in 
the tree. The scale represents expected substitutions per site. HLA-C*05:01:01:01 (red), HLA-C*07:02:01:03 (blue), other HLA-C alleles (black) and chimpanzee 
Patr-C alleles (black bold) are shown. 
Figure 9
Fig. 9 - Patterns of genetic diversity in human HLA-C alleles at three 
regulatory sites
Each grid represents the similarity between a HLA-C allele and the HLA-
C*05:01:01:01 and HLA-C*07:02:01:03 alleles, and it is coloured based on its 
similarity to C*05. Similarity is determined through phylogenetic analysis at 
the promoter/5’UTR, exon 2-3, and 3’UTR regions. The display of HLA-C 
subgroup alleles is based on their similarity ranking in the exon 2-3 region. 
Inferred trees utilised to extract these similarities are presented in 
Supplementary Fig. 6. 
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Fig. 10 - The regulatory landscape of HLA-C expression
A combination of variants in the 5’UTR, the antigen-binding cleft, and the 3’UTR, and potentially other yet unidentiﬁed factors, drive differential HLA-C 
expression at the cell-surface. 
Figure 10
